Introduction {#s1}
============

Multiple neurobiological pathways have been implicated in the physiopathology of bipolar disorder (BD). Oxidative stress ([@CIT0007]; [@CIT0063]) and mitochondrial dysfunction number amongst these pathways ([@CIT0065]). Although these 2 processes are closely integrated, published reports have generally focused on only one of these abnormalities at a time. Proton magnetic resonance spectroscopy (^1^H-MRS) is a noninvasive method that allows in vivo detection of metabolic alterations in localized brain areas (voxels). With regard to BD, previous studies based on standard 1-dimensional ^1^H-MRS protocols report a possible glycolytic shift evidenced by abnormalities in the glutamate to glutamine ratio ([@CIT0065]; [@CIT0062], [@CIT0064]). Two-dimensional (2D) J-resolved ^1^H-MRS techniques allow the measurement of small signal metabolites such as lactate (Lac), the main metabolic marker of mitochondrial dysfunction, and glutathione (GSH), the predominant brain antioxidant. Currently, there are no 2D J-resolved ^1^H-MRS studies reporting measures of both Lac and GSH concomitantly in BD. Measuring these 2 metabolites at the same time in vivo provides a unique opportunity to test the hypotheses of altered redox state and its association with mitochondrial dysfunction in BD.

Mitochondria play a crucial role in ATP production through oxidative phosphorylation, a process carried out by the respiratory chain complexes I, II, III, and V ([@CIT0051]; [@CIT0059]; [@CIT0014]). When mitochondrial function is inhibited or insufficient, anaerobic glycolysis is activated, leading to higher production of Lac. Thus, the accumulation of Lac occurs when oxidative phosphorylation is unable to meet energy requirements and the cell is forced to rely on the glycolytic process ([@CIT0055]). In general, mitochondrial dysfunction contributes to neurodegeneration either by apoptosis or generation of reactive oxygen species (ROS). ROS such as hydrogen peroxide, superoxide, and hydroxyl radicals are produced as by-products of mitochondrial phosphorylation ([@CIT0034]; [@CIT0010]; [@CIT0019]; [@CIT0026]). Under these circumstances of elevated levels of Lac and ROS, the GSH system, as the major brain antioxidant, has a fundamental role.

The GSH system is especially important for cellular defense against ROS, as GSH is the major antioxidant in the brain. This system comprises the enzymes that synthesize GSH within cells as well as dedicated enzymes that use GSH as the means to exert antioxidant effects ([@CIT0023]). GSH reacts directly with radicals in nonenzymatic reactions and is the electron donor in the reduction of peroxides catalyzed by GSH peroxidase. Astrocytes appear to contain higher GSH levels than neurons both in vivo and in culture ([@CIT0023]). There are few reports about abnormalities of the GSH system in BD regarding altered enzymes that use GSH as a cofactor (GSH reductase, GSH S-transferase, GSH peroxidase), but the interpretation of findings is limited by the heterogeneous methodologies used ([@CIT0009]). Studies conducted on peripheral blood cells have shown that BD is associated with increased levels of GSH reductase and GSH S-transferase in the late stage of the illness ([@CIT0003]). Moreover, low GSH S-transferase levels have been reported in postmortem prefrontal cortex from patients with BD, major depressive disorder, and schizophrenia ([@CIT0031]). Additionally, elevated GSH peroxidase in peripheral blood has been reported in BD depressive episodes ([@CIT0002]; [@CIT0022]) but not in mania or euthymia ([@CIT0001]; [@CIT0042]; [@CIT0003]; [@CIT0053]).

Previous ^1^H-MRS studies investigating GSH are scarce in BD, because standard techniques are not sufficiently sensitive to detect metabolites present in low concentrations, such as GSH. Our review identified 5 previous MRS studies on GSH in BD, all of which included a mixed sample of BD patients (type I, I, or NOS) in mania, depression, or euthymia ([@CIT0015], [@CIT0016], [@CIT0017]; [@CIT0015]; [@CIT0032]). All of these studies reported no differences in GSH levels between BD and controls in anterior cingulate (ACC) ([@CIT0015], [@CIT0016]; [@CIT0015]), prefrontal/occipital voxels ([@CIT0032]), or hippocampus ([@CIT0017]). With the objective of confirming an absence of differences in GSH between BD patients and HC we, studied a large and homogeneous sample of euthymic BD type I patients. Furthermore, the 2D-J resolved-PRESS ^1^H-MRS technique was employed for its greater sensitivity in detecting small GSH signals compared with the conventional ^1^H-MRS technique used in previous studies.

Previous evidence on oxidative stress in BD has shown alterations in antioxidant enzymes and lipid peroxidation in different states and stages of BD ([@CIT0007]). Superoxide dismutase and catalase activity have been reported to be altered in BD mood episodes ([@CIT0002]; [@CIT0046]). Evidence for oxidative stress in BD has been found in the form of lipid peroxidation and reduced Na+-K+-ATPase activity, alterations that can be counteracted by lithium treatment ([@CIT0006]). Moreover, decreased plasma levels of total GSH, together with lower catalase expression, increased protein carbonyls, 4-HNE, and 3-NT, were found in BD patients ([@CIT0053]; [@CIT0005]). Mitochondrial abnormalities in BD patients displayed decreased attachment of hexokinase 1 to outer mitochondrial membrane and decreased Complex I levels ([@CIT0005]).Moreover, there is some evidence indicating that the lifetime number of manic episodes increases oxidative damage to guanosine in BD, where our group previously reported an association between elevated levels of 8-OHdG and number of manic episodes ([@CIT0063]).

Elevated Lac has been considered a marker of mitochondrial dysfunction in BD ([@CIT0065]). Brain Lac, a metabolic product of glycolysis, plays an integral role in neuronal energy metabolism ([@CIT0058]). Lac exists in the healthy brain at low basal concentrations, and elevations can indicate transient changes in physiological state ([@CIT0020]) or neural activation ([@CIT0028]). Lac is a metabolite that is hard to measure due to its low concentration as well as to difficulties distinguishing the Lac signal from that of overlapping lipids and macromolecules, where specific ^1^H-MRS methods are required to reliably detect Lac ([@CIT0055]). The 4 previous ^1^H-MRS studies on Lac comparing BD patients with controls have reported increased levels in patients with BD ([@CIT0021]; [@CIT0008]; [@CIT0018]; [@CIT0070]), but none have exclusively investigated BD type I euthymic patients. These studies have included a mixture of BD subjects in different mood episodes, where this might be problematic when studying Lac in BD, as far as antioxidative enzymes have been reported to be altered during mood episodes ([@CIT0002]; [@CIT0046]). Moreover, the majority of previous Lac ^1^H-MRS studies used a short echo-time (TE), which can obscure Lac detection because of an important overlap with lipids' signal in this region ([@CIT0055]).

Aims of the Study {#s2}
-----------------

The aim of this study was to measure simultaneously dorsal ACC (dACC) levels of Lac and GSH in euthymic BD type I and healthy controls (HC), using in vivo 2D ^1^H-MRS. We hypothesized that BD patients present higher levels of Lac and lower levels of GSH based on the assumption of increased redox state and mitochondrial dysfunction in BD.

Methods {#s3}
=======

Eighty-eight subjects were included in this study. Of these, 50 (31 F, 18--45 years old) were euthymic BD I subjects and 38 (15 F, 18--45 years old) were HC. Diagnoses were made by trained psychiatrists based on the Structured Clinical Interview ([@CIT0027]) for DSM-IV TR ([@CIT0024]). The subjects had been on stable medication regimens for at least 2 months prior to the scanning session. Subjects with neurological disorders or medical disorders, head trauma, or current/past (3 months) substance abuse, as well as those who had been treated with electroconvulsive therapy in the last 6 months were excluded. Moreover, subjects reporting heavy episodic drinking (consuming 5 or more standard drinks \[male\], or 4 or more drinks \[female\] over a 2-hour period) ([@CIT0050]) over the past 3 months were excluded. The Young Mania Rating Scale ([@CIT0071]) and the Hamilton Depression Rating Scale ([@CIT0035]) were used to assess residual subthreshold depressive and manic symptoms. Euthymia was defined as \<7 Young Mania Rating Scale and \<7 Hamilton Depression Rating Scale. The patients also fulfilled the DSM-IV criteria for remission.

All HC had no current or past history of psychiatric disorders according to the evaluation conducted by trained psychiatrists using the Mini International Neuropsychiatric Interview ([@CIT0060]). In addition, HC subjects had no family history of mood or psychotic disorders among first-degree relatives based on a semistructured interview.

The research ethics committee CEP CAPPesq from the University of Sao Paulo approved the study. Written informed consent was obtained from all study participants.

Image Acquisition {#s4}
-----------------

All MRI exams were performed on a Philips 3T Achieva scanner (Philips Healthcare, Best, The Netherlands) using an 8-channel head coil. Spectroscopy measurements were performed using the maximum echo sampled JPRESS sequence proposed by [@CIT0056]. The JPRESS sequence is based on the conventional PRESS spin-echo technique used for selection of a single voxel. By varying the echo time of the acquisition, the J coupling evolution is encoded in an additional dimension. This technique is therefore also known as 2-dimensional spectroscopy, whereby the signal is measured as a function of chemical shift expressed by the Larmor frequency (as in conventional 1-dimensional spectroscopy) but also as a function of the coupling constant J in Hz. With the information of the coupling constant J, it is possible to resolve the signals from overlapping multiplets, such as Lac and GSH. In this study, the JPRESS sequence was used to evaluate a voxel of 20mm (L-R) x 20mm (I-S) x 45mm (A-P) (total voxel size 18cm^3^) in the dACC region, as shown in [Figure 1](#F1){ref-type="fig"}. The minimum TE used was 31ms, and TE was incremented in 100 steps of 2ms each. For each time increment ΔTE, the maximum-echo sampling started the acquisition ΔTE/2 earlier with respect to the echo top ([@CIT0056]). The repetition time (TR) was 1600ms, and 8 averages were acquired for each TE step. One non-water suppressed spectrum was also acquired at each TE. The number of points per spectrum was 1024, and the spectral bandwidth was 2000 Hz. An automatic second-order B~0~ shimming routine was used and water suppression was achieved by VAPOR ([@CIT0067]). Spectroscopy acquisition took 24 minutes, and the total exam duration, including volumetric imaging and voxel planning, was about 45 minutes. Metabolite quantification was obtained using ProFit (PRiOr knowledge FITting) version 2.0 running on Matlab R2011b ([@CIT0029]). The first version of ProFit was developed by Schulte et al. ([@CIT0056]) to fit 2D JPRESS data by extending LCModel ([@CIT0052]) principles to 2D data sets. In ProFit, as in the LCModel approach, the prior knowledge comes from a known metabolite basis set (experimentally acquired or calculated) used in the fitting process, and the VARPRO approach ([@CIT0068]) is used to separate the optimization of nonlinear and linear parameters for faster convergence. [@CIT0029] improved the quantification program (ProFit version 2.0) by introducing an experimentally acquired 2D macromolecular baseline into the fitting model and allowing for a more accurate and precise fit by accounting for the actual line shape and additional baseline distortions by self-deconvolution and spline modeling approaches.

![Magnetic resonance spectroscopy (MRS) voxel location in the sagittal plane. Size 20 x 20 x 45mm^3^.](ijnppy_pyw032_f0001){#F1}

The metabolite basis set used by ProFit includes spectra from a total of 18 brain metabolites including the metabolite of interest in this study: Lac and GSH. Basis set metabolite spectra were calculated with the GAMMA library ([@CIT0061]) using the chemical shift and J-coupling values from the literature ([@CIT0025]; [@CIT0033]). Quantitative results in ProFit are given in the form of ratios to Cr signal (met/Cr). These ratios are already corrected for T2 relaxation effects, since ProFit automatically calculates T2 relaxation times for each metabolite from the signal obtained at the different TEs. "Pseudo" absolute metabolite values \[met\] were obtained by assuming a white matter (WM) Cre concentration of 4.83mM (mmol/L) and a grey matter (GM) Cre concentration of 9.59mM, as expressed in the equation below. These Cr values in mM were calculated from previously reported Cr concentrations in units of mmol/kg ([@CIT0030]), as used previously ([@CIT0064]; [@CIT0074]) and expressed in the following equation:
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T1 relaxation effects were corrected for, assuming a mono-exponential T1 relaxation with GM T1 of 1.46s and a WM T1 of 1.24s ([@CIT0048]).

*GM%* and *WM%* represent GM and WM volume percentages, respectively, in the selected MRS voxel, while f~GM~ and f~WM~ represent the fractions of Cr signal attributable to GM and WM, respectively. To determine the brain tissue composition contained in the MRS voxel of interest, 3-dimensional volumetric images were obtained using the 3D-T1- FFE (fast field echo) technique (FA=8°; TE/TR/TI=3.2/7/900ms) with an isotropic voxel size of 1mm^3^. Briefly, the brain tissue was extracted using the brain extraction tool, and segmentation into WM, GM, and CSF was achieved using the automated brain segmentation tool FAST ([@CIT0073]). Both tools are part of the FSL suite (<http://www.fmrib.ox.ac.uk/fsl>). Finally, the MRS voxel was overlaid on the segmented image using a Python-based script developed in-house, and percentages of WM, GM, and CSF were calculated for each voxel. The ProFit program also provides a Cramér-Rao lower bound (CRLB) ([@CIT0011]), a measure of the quality of the metabolite quantification, for each metabolite. CRLBs were noted for each metabolite. Excluding spectra with Lac CRLBs above a specific threshold (30%) is a common practice in the literature on Lac. However, it was recently shown that to do so might prevent the observation of real differences between groups ([@CIT0040]), so we decided not to set a CRLB cutoff point in this study to avoid a misinterpretation of our Lac results. Only data with a CRLB of 999% were discarded from the analysis, since this specific CRLB output denotes that the program failed to calculate a reliable CRLB.

Statistical Analysis {#s5}
--------------------

The sample was first tested for homogeneity. Categorical variables were analyzed using χ^2^ tests, whereas continuous variables were analyzed using *t* tests. Normality was checked using the Kolmogorov-Smirnov test. Significant differences in age and gender were observed in the sample and to prevent this potential bias from influencing results, age and gender correction was performed in all analyses. Normally distributed variables were compared between the 2 groups using ANCOVAs in which Lac or GSH were entered as a dependent variable, while age, gender, group, CSF (only for Lac), and f~GM~ were entered as covariates. To investigate the influence of medication use on Lac and GSH, we performed an ANCOVA test in which Lac or GSH were entered as a dependent variable and medication type (lithium, atypical antipsychotics, or anticonvulsants), age, gender, CSF (only for Lac), and f~GM~ were entered as covariates. To investigate the influence of illness duration or lifetime psychotic symptoms on metabolites, we used an ANCOVA test in which Lac or GSH was entered as dependent variable and illness duration or lifetime psychotic symptoms, age, gender, CSF (only for Lac), and f~GM~ were entered as covariates. Finally, to investigate the correlation between GSH and Lac, we performed a regression analysis controlled by age and gender. All statistical analyses were carried out using IBM SPSS version 20.

Results {#s6}
=======

After controlling for age and gender, significant differences were observed between BD patients and HC in voxel content for GM% (BD 52% vs HC 54%) (F=5.5, df=88, *P*=.02) and CSF% (BD 25% vs HC 23%) (F=6.2, df=88, *P*=.01), but no differences were observed in WM content (BD 23% vs HC 23%) (F=0.4, df=88, *p P*=.48). Given the observed differences between HC and BD in voxel composition, we also performed a more detailed segmentation analysis of the brain tissue contributing to the spectrum by overlaying the ^1^H-MRS voxel on to structural maps segmented by FreeSurfer software (<https://surfer.nmr.mgh.harvard.edu>). This volumetric analysis is part of a separate publication including a larger cohort of BD patients (M. G. Soeiro-de-Souza and M. C. Garcia Otaduy, unpublished observations). Results of the MRS voxel overlay onto the segmented volumetric images indicate that the cortical structure driving this difference in voxel brain tissue composition was the caudal ACC, which was reduced in BD compared with HC (HC=16.5±3.5% vs BD=14.1±3.8%; *P*=.005). As a result, BD subjects had lower GM volume and higher CSF volume within the MRS voxel. These differences were compensated for in the statistical analysis by inclusion of f~GM~ (as described above in Image acquisition) as a variable in the statistical model. When comparing Lac between groups, CSF% was also considered as a covariate, since Lac can be present in CSF. GSH was present and quantifiable for all patients with a mean CRLB of 3.98% (1.37%-5.71%). Group characteristics for the GSH analysis are described in [Table 1](#T1){ref-type="table"}. There was no statistically significant difference in GSH levels between groups, although the BD group had higher mean levels (f=2.9, df=88, *P*=.08) (BD mean 1.32±0.31; HC mean 1.24±0.14).

###### 

Subject Demographic and Clinical Information for GSH MRS

                                                 **Healthy Controls**   **Bipolar I Disorder**
  ---------------------------------------------- ---------------------- ------------------------
  Age (y), mean ±SD                              25.7 ±5.7              31.7 ±9.1
  Gender (male/female)                           23/15                  19/31
  HDRS, mean ±SD                                                        3.7 ±2.1
  YMRS, mean ±SD                                                        2.4 ±2.1
  Illness duration, mean ±SD                                            9.1±7.6
  Lifetime psychotic symptoms (yes/no)                                  15/35
  Mean GSH 1.24 ±0.14                                                   1.32 ±0.31
  Mean GSH CRLB 3.94 ±0.33                                              4.00 ±0.67
  Anticonvulsants (valproate or carbamazepine)                          n=23
  Lithium                                                               n=29
  Atypical antipsychotics                                               n=23

Abbreviations: HDRS, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale; y, years; SD, standard deviation; Lac, lactate; CRLB, Cramér-Rao Lower Bound.

Regarding the Lac MRS, 16 individuals (3 HC and 13 BD) were excluded for having a CRLB of 999%, indicating lipid contamination or other artifacts ([supplementary Table 1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyw032/-/DC1)). Therefore, the sample used for Lac analysis consisted of 37 BD and 35 HC ([Table 2](#T2){ref-type="table"}). A statistically significant difference in Lac level was observed between the groups; the BD group had higher mean levels (F=5.49, df=72, *P*=.02) (BD mean 0.31±0.15; HC mean 0.24±0.09) compared with the HC group ([Figure 2](#F2){ref-type="fig"}). As [supplementary material](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyw032/-/DC1), an analysis was performed considering CRLB\<30% (sample size BD=26 x HC=26), whose outcome supported the result of higher Lac in BD (F=5.0, df=52, *P*=.02) ([supplementary Table 2](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyw032/-/DC1)).

###### 

Subject Demographic and Clinical Information for Lactate MRS (n=72)

                                                 **Healthy Controls**   **Bipolar I Disorder**
  ---------------------------------------------- ---------------------- ------------------------
  Age (y), mean ±SD                              25 ±4.5                31.1 ±9.3
  Gender (male/female)                           23/12                  13/24
  HDRS, mean ±SD                                                        3.1 ±1.9
  YMRS, mean ±SD                                                        2.7 ±2
  Illness duration, mean ±SD                                            8.8±7.2
  Lifetime psychotic symptoms (yes/no)                                  11/26
  Mean Lac 0.24 ±0.09                                                   0.31 ±0.15
  Mean Lac CRLB 28.8 ±15.6                                              32.7±36.3
  Anticonvulsants (valproate or carbamazepine)                          n=16
  Lithium                                                               n=22
  Atypical antipsychotics                                               n=18

Abbreviations: HDRS, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale; y, years; SD, standard deviation; Lac, lactate; CRLB, Cramér-Rao Lower Bound.

![Mean dorsal anterior cingulate cortex (dACC) levels of lactate (Lac) in bipolar disorder (BD) type I compared with healthy controls (HC).](ijnppy_pyw032_f0002){#F2}

We observed a positive correlation between Lac and GSH levels in BD (B=0.20, t=3.2, *P*=.003, CI=0.07--0.33) but not in HC (B=0.17, t=1.64, *P*=.11, CI=-0.04--0.39) ([Figure 3](#F3){ref-type="fig"}). When we perform this analysis without correcting for age, gender, or f~GM~, we observed the same results: in BD, Lac was correlated with GSH (B=0.21, t=3.44, *P*=.002, CI=0.08--0.33), while in HC there was no correlation between these 2 metabolites (B=0.19, t=1.8, *P*=.07, CI=-0.01--0.41).

![Correlation between dorsal anterior cingulate cortex (dACC) levels of lactate (Lac) and glutathione (GSH) adjusted for age and gender.](ijnppy_pyw032_f0003){#F3}

Neither illness duration nor the presence of lifetime psychotic symptoms demonstrated to influence any of the metabolite measures (*P*\<.05). There was no influence of lithium, atypical antipsychotics, or anticonvulsants on Lac or GSH levels.

Discussion {#s7}
==========

In the present study, higher dACC Lac levels were found in euthymic BD type I patients compared with HC. No significant differences in GSH were observed, but a positive correlation between Lac and GSH level was detected. Moreover, no influence of medications on metabolite levels was found.

Our results revealed increased Lac in BD regardless of medication use, supporting the hypothesis of mitochondrial dysfunction in BD ([@CIT0065]). Mitochondrial dysfunction occurs when oxidative phosphorylation is unable to meet energy requirements and the cell is forced to rely on the glycolytic process, which increases the production of Lac ([@CIT0049]). Some studies have reported higher Lac concentrations in the CSF of BD patients ([@CIT0054]). Furthermore, postmortem studies have found decreased expression of mitochondrial genes encoding the electron transport chain ([@CIT0038]; [@CIT0066]) and abnormal mitochondrial complex I activity ([@CIT0004]) in brain of BD individuals. Moreover, the presented data are reinforced by other MRS studies reporting lower intracellular pH ([@CIT0036]; [@CIT0037]), decreased N-acetyl aspartate ([@CIT0012]; [@CIT0013]), and higher Glx ([@CIT0072]; [@CIT0062]). Findings of increased Glx in bipolar subjects suggest that the hypothesized glycolytic shift underlying the pathology of BD may be linked to some degree of glutamate-induced neuronal hyperactivation ([@CIT0065]).

Our data evidencing increased Lac in BD is in agreement with the majority of previous Lac ^1^H-MRS studies involving mania, depression, and euthymia ([@CIT0021]; [@CIT0018]; [@CIT0070]). Only one study, by [@CIT0008] reported lower Lac levels in BD patients (n=7) compared with HC. [@CIT0008] reported that Lac levels in mania (n=7) were increased compared with HC in the parietal occipital cortex and ACC. However, when these same patients were in euthymia after treatment, their Lac levels were lower (n=7) than those of HC (n=6) ([@CIT0008]). Chu et al. investigated Lac levels (4T scanner) in a sample of 21 BD patients in euthymia and mixed episode compared with 10 HC. The group reported increased Lac levels in BD patients, symptomatic or otherwise ([@CIT0018]). The other 2 studies comparing Lac levels in BD patients with HC reported increased levels of Lac in the ACC of BD patients during mania, depression, and mixed state ([@CIT0021]; [@CIT0070]). Three of the 4 Lac MRS studies described CRLB levels and used a CRLB cutoff for inclusion of subjects in the study. [@CIT0008] included individuals with CRLB\<26%, while [@CIT0070] and [@CIT0018] included those with CRLB≤30%. A known problem with measuring Lac is systematic overestimation when using linear combination fitting algorithms to estimate concentrations ([@CIT0039]). Excluding spectra with Lac CRLBs above a specific threshold (30%) is a common practice in the literature on Lac, since CRLBs are linked to chemical estimation reliability. However, due to the difficulty discriminating the Lac signal from background noise, the meaning of the CRLBs produced by LCModel for this metabolite is less clear. Kreis et al. ([@CIT0041]; [@CIT0040]) reported that using CRLB threshold as an exclusion criterion can lead to false conclusions and suggested that quality checks should be based on metabolites present at higher concentrations. Therefore, we decided not to set a CRLB cutoff point in this study to avoid misinterpretation of our Lac data, and by doing so, the mean CRLB of Lac in this study was 30.8%. [Supplementary Table 2](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyw032/-/DC1) demonstrates that inclusion of only individuals with CRLB\<30% would have yielded a smaller sample size (BD, n=26; HC, n=26) with similar results.

Our GSH data are in agreement with the 5 previous MRS studies on GSH in BD ([@CIT0015], [@CIT0016], [@CIT0017]; [@CIT0015]; [@CIT0032]). All studies reported no differences in GSH levels between BD and controls within different voxels but included BD type I, II, and BD spectrum during all mood episodes. Two of these studies reported a negative association between alcohol and tobacco use with GSH levels in the ACC that was specific to BD patients ([@CIT0015], [@CIT0016]). A longitudinal study reported that elevated GSH levels in the hippocampus were associated with lower alcohol consumption and frequency of tobacco use ([@CIT0017]). Based on our data, from a sample that included exclusively euthymic patients, taken together with previous GSH ^1^H-MRS studies, it can be concluded that the levels of GSH measured by ^1^H-MRS do not differ between BD patients and HC regardless of mood state. In BD patients, we found a correlation between Lac and GSH, where higher Lac was associated with higher GSH levels. We hypothesize that the positive correlation found between GSH and Lac could be related to the presence of a physiological compensatory mechanism, in which there is an increase in GSH levels as Lac levels increase. Similar results have been observed in early-stage schizophrenia and posttraumatic stress disorder, where a higher GSH was noted in subjects with greater oxidative stress ([@CIT0047]; [@CIT0069]). We hypothesize that both BD and HC groups had different patterns of correlation between Lac and GSH, because the patients were medicated and stable, allowing a compensatory response of GSH to increased mitochondrial dysfunction. Therefore, we speculate that the association between Lac and GSH is impaired during acute mood episodes.

A limitation to studying euthymic BD type I patients is the difficulty finding subjects without symptoms who are not under medication treatment. Therefore, the use of medications should always be controlled as a cofactor in this type of study. Consequently, we can only state that the findings reported are the result of an interaction among all the factors and probably a metabolic feature of euthymic medicated BD type I patients. Moreover, the present sample of BD patients differed from HC for age and gender, although these variables were controlled for in all analysis. Furthermore, the differences in tissue voxel composition observed between BD patients and HC are probably explained by cortical thinning, previously reported for BD ([@CIT0045]) and major depressive disorder ([@CIT0044]). In congruence with this phenomenon, we found a smaller contribution of the caudal ACC cortex to the total brain tissue in the MRS voxel among BD patients compared with HC. To compensate for this variation, the f~GM~ and CSF% were considered in the statistical analysis.

To the best of our knowledge, this investigation had the largest sample size for an MRS study of Lac and GSH in euthymic BD type I patients. Our data showed that BD type I patients had higher levels of Lac in the dACC, which could be an indication of altered mitochondrial function and a glycolytic shift in BD even during euthymia. Moreover, Lac correlated with GSH levels regardless of BD diagnosis, indicating a physiological association between the antioxidative system and mitochondrial dysfunction.
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